Agenda
• 3:00-3:30 PM Networking, Registration & Tour
• 3:30-5:00 PM Expert Panel
• 5:00-6:30 PM Networking Reception

We have seen significant changes in M&A activity in the life sciences industry, but how does that affect the future of your company and the industry as a whole? Has M&A stalled or are deals fewer and far between but larger in scope? Alternatively, has the pace quickened but with monumental changes to the structure of a deal? Most importantly, how can you position your company to make acquisition an attractive option?

Join this panel to hear M&A strategy perspective from the acquirer and the acquired, the investor, and the lawyer.

You will have the opportunity to meet Peter McWilliams, Ph.D., Principal at Sanderling Ventures, and Chairman & Acting CEO of Actimis, a biopharmaceutical company currently being acquired by World Bio-giant Boehringer Ingelheim GmbH for as much as $515 million.

You will learn:
• How to identify the good target buyer, and how to approach him
• Valuation challenges and strategies
• Is M&A your best bet
• How to structure the deal
• What to expect after the acquisition
• What are the relative advantages of pursuing a M&A over other transactions
• What are the risks of a M&A and how to mitigate theses risks
• How to plan a successful exit.

Invited Speakers
• Peter McWilliams, Ph.D., Principal, Sanderling Ventures, and Chairman & Acting Chief Executive Officer of Actimis Pharmaceuticals (currently being acquired by Boehringer) Click Here for Bio»
• Ellen Koskinas, Partner, InterWest Partners LLC Click Here for Bio»
• Corey Goodman, President, Biotherapeutics and Bioinnovation Center, Pfizer Click Here for Bio»
• Richard Douglas, Ph.D., Senior Vice President of Corporate Development, Genzyme Corporation Click Here for Bio»
• John A. Scarlett, M.D., Chief Executive Officer, Tercica, Inc. Click Here for Bio»
• Robert Thomas, CEO, Corium International, Inc.
• Lead Facilitator: Mark W. Seneca, Partner, Corporate Group, Orrick, Herrington & Sutcliffe LLP Click Here for Bio»


Cost & Registration
• Panel + Networking Reception:
     ° Regular Price: $40
     ° Partners' Network: $30
     ° BioCenter Members: Free
• Networking Reception only: $20
• On-site Registration, if space allows: add $10 to the above
This event is typically sold out, therefore please register early to secure your spot.

Save time and money: register to more 2008 Panels!
Dec. 11: Holiday Celebration & Trends In Financing Investor Panel


Event Sponsor: Henkel Loctite
For more than 130 years, Henkel has been a leader with brands and technologies that make people's lives easier, better, and more beautiful. Henkel operates in three business areas -- Home Care, Personal Care, and Adhesives Technologies -- and ranks among the Fortune Global 500 companies.
Henkel offers Loctite® brand medical device adhesives: the industry’s most comprehensive line of ISO-10993 compliant materials for medical device assembly. Loctite brand medical device adhesives are offered in all the major categories including Light Cure, Cyanoacrylate, Epoxy, Urethane, and Silicone. Henkel also offers a full line of dispensing, light cure, and process monitoring equipment to ensure accurate application, curing and identification of adhesive on-part.


Speakers Bios

Peter McWilliams, Ph.D., Principal, Sanderling Ventures, and Chairman & Acting Chief Executive Officer of Actimis Pharmaceuticals (currently being acquired by Boehringer)
Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works with several Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Trinity Biosystems, Artielle Immunotherapeutics, Actimis Pharmaceuticals, Harkness Pharmaceuticals, Cylene Pharmaceuticals and others.
Prior to joining Sanderling, Dr. McWilliams worked at Genentech (NYSE: DNA) where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin™. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. From 1991 to 1994 he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics where, as a Product Manager and Applications Specialist, he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange in 1994.
Dr. McWilliams received an M.B.A. from Columbia Business School in 1996, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. in 1991 and an M.A. in 1990 in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University in 1987.
Ellen Koskinas, Partner, InterWest Partners LLC
Ellen Koskinas focuses on life sciences investing, with an emphasis on medical devices. She is a board member of Applied Spine Technologies, Apsara Medical, CardioMind, EnteroMedics and Neuronetics. She has also been an active observer on the boards of Epicor (acquired by St. Jude Medical), NeuroPace and Paracor Medical. Prior to InterWest, Koskinas held a number of key roles in marketing and business development at Guidant Corporation, where she built a new business in minimally invasive cardiac surgery and then led Guidant's acquisition of CardioThoracic Systems. Koskinas has also served as an Engagement Manager for McKinsey & Company, managing projects for a broad range of pharmaceutical, healthcare delivery and medical device clients. At the outset of her career, she worked in corporate finance at Morgan Stanley in New York and London. Koskinas received a B.A. in economics with honors from Harvard College and received a M.B.A. from the Stanford Graduate School of Business.
Corey Goodman, President, Biotherapeutics and Bioinnovation Center, Pfizer - TBC
Corey Goodman is the President of Pfizer’s Biotherapeutics and Bioinnovation Center based in San Francisco. He oversees this newly established entrepreneurial center which is focused on translating biomedical discoveries into new medicines. The center is both independent and interdependent on Pfizer Global Research and Development (PGRD), creating and overseeing a consortium of units and collaborations with the academic, biomedical, biotech and venture capital communities, while collaborating closely with PGRD. Corey joined Pfizer to head the Biotherapeutics and Bioinnovation Center in October 2007. Born in Chicago, Corey attended Stanford University as a Searle Scholar and earned his B.S. in Biology with distinction and honors. He was an NSF Fellow at the University of California Berkeley and earned his Ph.D. in Neurobiology. He was then a Helen Hay Whitney Postdoctoral Fellow at U.C. San Diego. He was a Professor at Stanford University and U.C. Berkeley for over two decades, and is currently Adjunct Professor at U.C. Berkeley. While on the faculty at Berkeley, Corey was an Investigator with the Howard Hughes Medical Institute, Evan Rauch Professor of Neuroscience, co-founder of the Wills Neuroscience Institute, and Head of the Division of Neurobiology. Corey was elected a member of the U.S. National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, and a member of the American Philosophical Society. Among his many scientific honors are the Alan T. Waterman Award from the National Science Board, the Gairdner Foundation International Award for Achievement in Medical Sciences, the Wakeman Award, the March of Dimes Prize in Developmental Biology, and the Reeve-Irvine Research Medal. Corey has advised numerous biotechnology companies, and co-founded two of them: Exelixis and Renovis. He served as the President and Chief Executive Officer of Renovis from 2001 until 2007 when the company’s merger with Evotec was announced. Among his many public service roles, Corey is Vice President of the McKnight Endowment Fund for Neuroscience, a member of the California Council on Science and Technology, and a member of the boards of BayBio and the Bay Area Science and Innovation Consortium (BASIC). He is former Chair of the National Research Council’s board on Life Sciences.
Richard Douglas, Ph.D., Senior Vice President of Corporate Development, Genzyme Corporation - TBC
Richard Douglas joined Genzyme in 1989. He is responsible for evaluating and acquiring new products, programs and companies for the corporation. Dr. Douglas helps develop growth plans for Genzyme and each of its business units and subsidiaries. Prior to joining Genzyme, Dr. Douglas was director of new product development at Integrated Genetics. He has also served as the company’s manager of protein chemistry research. Dr. Douglas had a post doctoral fellowship at the California Institute of Technology and received his Ph.D. in biochemistry from the University of California, Berkeley. He also has a B.S. from the University of Michigan.
John A. Scarlett, M.D., Chief Executive Officer, Tercica, Inc. - TBC
Dr. Scarlett established Tercica's U.S. operations in May 2002 after serving as Chief Executive Officer of Sensus Drug Development Corporation, another Genentech licensee. He previously co-founded Covance Biotechnology Services and held senior management positions at the North American Clinical Development Organization, Novo Nordisk Pharmaceuticals, Greenwich Pharmaceuticals, and McNeil Pharmaceuticals. Dr. Scarlett graduated with honors from the University of Chicago's Pritzker School of Medicine. He trained in internal medicine at the Hospital of the University of Pennsylvania, and in endocrinology and metabolism at the University of Colorado.
Lead Facilitator: Mark W. Seneca, Partner, Corporate Group, Orrick, Herrington & Sutcliffe LLP
Mark Seneca, a partner in the Silicon Valley office, is a member of the Emerging Companies Group. Mr. Seneca focuses on the representation of publicly traded and privately held companies in both buy-side and sell-side merger and acquisition transactions primarily in the technology sector. Among Mr. Seneca's past and current buy-side clients are Symphony Service Corp, Intellisync Corporation (sold to Nokia Corporation), Xilinx, Inc. and The Resource Group International Limited. In addition, Mr. Seneca has served as lead M&A counsel on numerous sale transactions involving major technology sector participants, including IBM, Computer Associates International, Alcatel and SSA Global Technologies. Mr. Seneca also has significant experience representing emerging growth technology companies and their investors in formation matters, capital financings and public offerings. Prior to joining the firm, Mr. Seneca was a senior member of Venture Law Group's firmwide Mergers and Acquisitions Group.

Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»